Theralase Technologies Inc. V.TLT

Ph 1b patients #5 and #6 still cancer free after 2 years

[ScienceFirst]

« … with patients five and six demonstrating CR with no presence, recurrence or progression of the disease at up to 24 months post treatment."

All this, with one dose!

The holy grail of oncology; 

- high efficacy,
- low number of treatments (1 in our case)
- no side effects,
- total destruction of the late-stage solid tumor.

You cannot ask for anything better than that.

[Infinity]

Science First, I get your point. Loud and Clear. 1. I am perplexed by the market valuation at $ 0.30 +/_ for many years now. 2. The big pharma companies are ignoring TLT for a reason. Or the Management is not disclosing the interest shown by Big Pharma. Or even worse, the Board is trying to ignore the Interest of the Share holders.

[langosta]

Surely big pharma would not be deliberately suppressing our market value over these many years by any of the various means available to them.  Why that would be positively criminal, and we all know that big pharma are so squeaky clean that they would never stoop to such shenanigans. https://violationtracker.goodjobsfirst.org/industry/pharmaceuticals

[ScienceFirst]

Langosta ... It's all about market shares. Whether you're TESLA, AMAZON, MERCK, GOOGLE, FACEBOOK, etc ... You're the CEO of a big pharma and have stock options.  Why would you let an opportunity run away?  Why would you let a competitor shift you? TLT had its Ph. 2 to do.  It won't even be completed until 2025.  What was the rush for those big pharmas, when

[langosta]

I know it's all about market share. As far as large corporations are concerned that can often be described ib one word, "Greed" or perhaps, "Ego". After all, who gets hurt when a company is caught in some impropriety? CEO's, Company Boards, Directors? I don't think so. As long as  the company can claim "Personhood" then it's the company that pays

[ScienceFirst]

Langosta ... Again, you're the CEO of a big pharma and have stock options.  Why would you let an opportunity run away?  Why would you let a competitor shift you?

[ScienceFirst]

Infinity ... Quite possible that it's rather TLT that asked big pharmas to come back later when more Ph. 2 data is out.  When you have something you know everyone will want, that's the position you usually take.  You wait till the data is undisputable so you can have the best position when negociations come.   And I saw this for a biotech that was bought for 30B$US in

[skys1]

As I have posted several times before. TLT management is not business stupid. They know when they have commercialization approvals in hand, TLT will be worth far more than it's current valuation. Hence, no negotiations until BTD & AA are in hand which should be only several months away, then they will get down to some serious business. Then we will see a more viable valuation. It is surely

[enriquesuave]

Pretty awesome results  I suppose the FDA will see the same level of detail patient per patient as in article.  The potential Gold Standard statement by Dr Mandel makes sense if we can continue to demonstrate a high level of durable efficacy with 2 simple safe treatments.  Much less burdensome for patients and hospitals as well  IMhO  

[ScienceFirst]

In fact, both ph. 1b patients #5 and #6 have now reached their 3y+ milestone, as we speak, as the statement below was dated of August 2021 and that p#6 reached 540 days on Sept. 30, 2019, so initially treated around April 8, 2018. It's impossible that the FDA pass over such a treatment and not grant us Breakthrough designation and Accelerated Approval program, especially that this is for a